Comments
The Bengaluru-based Centre for Cellular and Molecular Platforms – C-CAMP – has been selected by CARB-X for its Global Accelerator Network, which comprises a league of 10 organisations to combat anti-microbial resistance (AMR).
C-CAMP, an initiative of the Centre’s Department of Biotechnology (DBT), is the only accelerator from outside the US and Europe, to be selected for the AMR. CARB-X GAN brings together 10 organisations from six countries (Denmark, Germany, India, Switzerland, the UK, the US) into a single global network of expertise to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects.
Threat to public health
The spread of drug-resistant bacteria, also known as superbugs, is a growing threat to public health and a concerted global effort is needed to develop new therapeutics, diagnostics and preventatives to combat them. The CARB-X GAN is a powerhouse of knowhow in anti-bacterial drug development, the development of rapid diagnostics, business and regulatory strategy, and other highly specialised areas essential to accelerating CARB-X’s portfolio of funded projects targeting drug-resistant bacteria.
Speaking about the partnership, Dr. Taslimarif Saiyed, CEO and Director, C-CAMP, said: “Antimicrobial resistance is a major global health challenge, more so, in India. We are excited about joining the CARB-X Global Accelerator Network, which supports innovative research targeting AMR in India and elsewhere in the world. We look forward to working with CARB-X-funded companies to support their innovative product development and collaborating with other accelerators in the network.”
Kevin Outterson, Executive Director of CARB-X and Boston University law professor said, “We are expanding our accelerator network to increase support for the development of new antibiotics, rapid diagnostics, vaccines and other life-saving products that the world so urgently needs to fight the rise of drug-resistant bacteria. Anti-bacterial product development is challenging, and CARB-X’s portfolio is growing rapidly. As a group, the Global Accelerator Network is an outstanding source of expertise and can ally in the global fight against drug-resistant bacteria.”
CARB-X GAN network
The CARB-X Global Accelerator Network (GAN) for projects is funded by CARB-X. CARB-X is the world largest public-private partnership devoted to early development antibacterial R&D. This was announced globally on February 26.
The CARB-X GAN comprises: the Centre for Cellular and Molecular Platforms - C-CAMP (Bengaluru, India), California Life Sciences Institute - CLSI (California, USA), MassBio (Boston, USA), RTI International (North Carolina, USA), the Wellcome Trust (London, UK), BaselArea.Swiss (Basel, Switzerland), BioInnovation Institute (Copenhagen, Denmark), Foundation for Innovative New Diagnostics – FIND (Geneva, Switzerland), German Center for Infection Research - DZIF (Braunschweig, Germany), and the Institute for Life Sciences Entrepreneurship - ILSE (New Jersey, USA).
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.